Zydus Cadila has received the final approval from the USFDA to market Cyproheptadine Hydrochloride Tablets USP, 4 mg. It is an antihistamine used to relieve allergy symptoms such as watery eyes, running nose, itching eyes or nose, sneezing, hives, and itching. 

The drug will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad. 

The group now has around 115 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company declined Rs 13.95, or 3.05%, to trade at  Rs 443.90.  The total volume of shares traded  was  233,485 at the BSE (1.01 p.m., Tuesday).